HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: 293/2/E604    most recent 00153.2007v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (4) Citing Articles via Google Scholar Google Scholar Articles by Sloth, B. Articles by Astrup, A. Search for Related Content PubMed PubMed Citation Articles by Sloth, B. Articles by Astrup, A.

Effect of subcutaneous injections of PYY_1-36 and PYY_3-36 on appetite, ad libitum energy intake, and plasma free fatty acid concentration in obese males

¹Department of Human Nutrition, Centre for Advanced Food Studies, Faculty of Life Sciences, University of Copenhagen, Frederiksberg; and ²Department of Medical Physiology, The Panum Institute, University of Copenhagen, Copenhagen, Denmark

Submitted 8 March 2007 ; accepted in final form 1 June 2007

Intraveneous (iv) PYY_3-36 infusions have been reported to reduce energy intake (EI) in humans, whereas few studies exist on effects of PYY_1-36. The aim of the present study was to examine effects of subcutaneous (sc) injections of PYY_1-36 and PYY_3-36 on appetite, ad libitum EI, plasma concentrations of PYY and free fatty acids (FFA) in obese males. Twenty-four males (BMI 27–40 kg/m²) were randomly assigned to two groups receiving sc injections of either PYY_1-36 or PYY_3-36 in a blinded, placebo-controlled, dose-escalating, cross-over study. Subjects were studied 5 days in succession, with escalating doses of PYY_1-36 [saline, 50, 100, 150, and 200 pmol PYY_1-36/kg lean body mass (LBM)], or PYY_3-36 (saline, 25, 50, 75, and 100 pmol PYY_3-36/kg LBM), respectively. PYY injections resulted in dose-dependent increases in plasma PYY levels but no effect on EI in either the PYY_1-36 or the PYY_3-36 group. However, increasing doses of PYY_3-36, but not PYY_1-36, resulted in increased ratings of satiety and decreased ratings of hunger, thirst, and prospective food consumption. Although not dose dependently, significant elevation of plasma FFA was seen after injection of PYY_3-36, but not PYY_1-36. Although sc administration of PYY was well tolerated, it remains to be determined whether high-dose PYY_3-36 is sufficient in reducing EI in long-term trials, and if so, whether the reduction in EI occurs without nausea. PYY_1-36 is unlikely to be important in regulating energy intake. The PYY_3-36 administrations caused a non-dose-dependent mobilization of FFA, likely through a direct effect.

peptide YY; lipolysis; catecholamine; hunger; satiety

This article has been cited by other articles:

				M. H. Tschop and E. Ravussin Peptide YY: obesity's cause and cure? Am J Physiol Endocrinol Metab, November 1, 2007; 293(5): E1131 - E1133. [Full Text] [PDF]